Literature DB >> 27192578

PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion.

Roberto Tinoco1, Florent Carrette2, Monique L Barraza2, Dennis C Otero2, Jonathan Magaña2, Marcus W Bosenberg3, Susan L Swain4, Linda M Bradley5.   

Abstract

Chronic viruses and cancers thwart immune responses in humans by inducing T cell dysfunction. Using a murine chronic virus that models human infections, we investigated the function of the adhesion molecule, P-selectin glycoprotein ligand-1 (PSGL-1), that is upregulated on responding T cells. PSGL-1-deficient mice cleared the virus due to increased intrinsic survival of multifunctional effector T cells that had downregulated PD-1 as well as other inhibitory receptors. Notably, this response resulted in CD4(+)-T-cell-dependent immunopathology. Mechanistically, PSGL-1 ligation on exhausted CD8(+) T cells inhibited T cell receptor (TCR) and interleukin-2 (IL-2) signaling and upregulated PD-1, leading to diminished survival with TCR stimulation. In models of melanoma cancer in which T cell dysfunction occurs, PSGL-1 deficiency led to PD-1 downregulation, improved T cell responses, and tumor control. Thus, PSGL-1 plays a fundamental role in balancing viral control and immunopathology and also functions to regulate T cell responses in the tumor microenvironment.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  P-selectin glycoprotein ligand-1; T cell exhaustion; cancer; immunopathology; inhibitory receptors; lymphocytic choriomeningitis virus clone 13; melanoma; programmed death-1

Mesh:

Substances:

Year:  2016        PMID: 27192578      PMCID: PMC4908967          DOI: 10.1016/j.immuni.2016.04.015

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  48 in total

1.  Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection.

Authors:  Rachael D Aubert; Alice O Kamphorst; Surojit Sarkar; Vaiva Vezys; Sang-Jun Ha; Daniel L Barber; Lilin Ye; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

2.  The P-selectin glycoprotein ligand-1 is important for recruitment of neutrophils into inflamed mouse peritoneum.

Authors:  E Borges; R Eytner; T Moll; M Steegmaier; M A Campbell; K Ley; H Mossmann; D Vestweber
Journal:  Blood       Date:  1997-09-01       Impact factor: 22.113

3.  Interaction of the selectin ligand PSGL-1 with chemokines CCL21 and CCL19 facilitates efficient homing of T cells to secondary lymphoid organs.

Authors:  Krystle M Veerman; Michael J Williams; Kenji Uchimura; Mark S Singer; Jasmeen S Merzaban; Silvia Naus; Douglas A Carlow; Philip Owen; Jesús Rivera-Nieves; Steven D Rosen; Hermann J Ziltener
Journal:  Nat Immunol       Date:  2007-04-01       Impact factor: 25.606

4.  Gene duplications at the chemokine locus on mouse chromosome 4: multiple strain-specific haplotypes and the deletion of secondary lymphoid-organ chemokine and EBI-1 ligand chemokine genes in the plt mutation.

Authors:  H Nakano; M D Gunn
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

5.  PSGL-1 regulates the migration and proliferation of CD8(+) T cells under homeostatic conditions.

Authors:  Krystle M Veerman; Douglas A Carlow; Iryna Shanina; John J Priatel; Marc S Horwitz; Hermann J Ziltener
Journal:  J Immunol       Date:  2012-01-16       Impact factor: 5.422

6.  PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells.

Authors:  Erin E West; Hyun-Tak Jin; Ata-Ur Rasheed; Pablo Penaloza-Macmaster; Sang-Jun Ha; Wendy G Tan; Ben Youngblood; Gordon J Freeman; Kendall A Smith; Rafi Ahmed
Journal:  J Clin Invest       Date:  2013-05-15       Impact factor: 14.808

7.  Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses.

Authors:  Frann Bennett; Deborah Luxenberg; Vincent Ling; I-Ming Wang; Kim Marquette; David Lowe; Nighat Khan; Geertruida Veldman; Kenneth A Jacobs; Viia E Valge-Archer; Mary Collins; Beatriz M Carreno
Journal:  J Immunol       Date:  2003-01-15       Impact factor: 5.422

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection.

Authors:  Michael A Paley; Daniela C Kroy; Pamela M Odorizzi; Jonathan B Johnnidis; Douglas V Dolfi; Burton E Barnett; Elizabeth K Bikoff; Elizabeth J Robertson; Georg M Lauer; Steven L Reiner; E John Wherry
Journal:  Science       Date:  2012-11-30       Impact factor: 47.728

10.  PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection.

Authors:  Constantinos Petrovas; Joseph P Casazza; Jason M Brenchley; David A Price; Emma Gostick; William C Adams; Melissa L Precopio; Timothy Schacker; Mario Roederer; Daniel C Douek; Richard A Koup
Journal:  J Exp Med       Date:  2006-09-05       Impact factor: 14.307

View more
  42 in total

Review 1.  PSGL-1: A New Player in the Immune Checkpoint Landscape.

Authors:  Roberto Tinoco; Dennis C Otero; Amy A Takahashi; Linda M Bradley
Journal:  Trends Immunol       Date:  2017-03-02       Impact factor: 16.687

Review 2.  Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting.

Authors:  Annalisa Contursi; Angela Sacco; Rosalia Grande; Melania Dovizio; Paola Patrignani
Journal:  Cell Mol Life Sci       Date:  2017-05-09       Impact factor: 9.261

3.  Hypomethylation of STAT1 and HLA-DRB1 is associated with type-I interferon-dependent HLA-DRB1 expression in lupus CD8+ T cells.

Authors:  Shaylynn Miller; Pei-Suen Tsou; Patrick Coit; Elizabeth Gensterblum-Miller; Paul Renauer; Dallas M Rohraff; Nathan C Kilian; Mark Schonfeld; Amr H Sawalha
Journal:  Ann Rheum Dis       Date:  2019-01-23       Impact factor: 19.103

Review 4.  Trial watch: Immune checkpoint blockers for cancer therapy.

Authors:  Claire Vanpouille-Box; Claire Lhuillier; Lucillia Bezu; Fernando Aranda; Takahiro Yamazaki; Oliver Kepp; Jitka Fucikova; Radek Spisek; Sandra Demaria; Silvia C Formenti; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-31       Impact factor: 8.110

5.  A Soluble Form of P Selectin Glycoprotein Ligand 1 Requires Signaling by Nuclear Factor Erythroid 2-Related Factor 2 to Protect Liver Transplant Endothelial Cells Against Ischemia-Reperfusion Injury.

Authors:  C Zhang; Y Zhang; Y Liu; Y Liu; S Kageyama; X-D Shen; F Gao; S Zheng; R W Busuttil; G D Shaw; H Ji; J W Kupiec-Weglinski
Journal:  Am J Transplant       Date:  2017-02-06       Impact factor: 8.086

6.  Targeting the PSGL-1 pathway for immune modulation.

Authors:  Roberto Tinoco; Linda M Bradley
Journal:  Immunotherapy       Date:  2017-09       Impact factor: 4.196

7.  ILDR2 Is a Novel B7-like Protein That Negatively Regulates T Cell Responses.

Authors:  Iris Hecht; Amir Toporik; Joseph R Podojil; Ilan Vaknin; Gady Cojocaru; Anat Oren; Elizabeta Aizman; Spencer C Liang; Ling Leung; Yosef Dicken; Amit Novik; Nadav Marbach-Bar; Aziza Elmesmari; Clare Tange; Ashley Gilmour; Donna McIntyre; Mariola Kurowska-Stolarska; Kay McNamee; Judith Leitner; Shirley Greenwald; Liat Dassa; Zurit Levine; Peter Steinberger; Richard O Williams; Stephen D Miller; Iain B McInnes; Eyal Neria; Galit Rotman
Journal:  J Immunol       Date:  2018-02-05       Impact factor: 5.422

Review 8.  VISTA: Coming of age as a multi-lineage immune checkpoint.

Authors:  M A ElTanbouly; E Schaafsma; R J Noelle; J L Lines
Journal:  Clin Exp Immunol       Date:  2020-02-04       Impact factor: 4.330

Review 9.  VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.

Authors:  Mohamed A ElTanbouly; Walburga Croteau; Randolph J Noelle; J Louise Lines
Journal:  Semin Immunol       Date:  2019-04       Impact factor: 11.130

10.  VISTA is an acidic pH-selective ligand for PSGL-1.

Authors:  Linhui Julie Su; Jason Pinckney; David Critton; Robert J Johnston; Eric Boyer; Arathi Krishnakumar; Martin Corbett; Andrew L Rankin; Rose Dibella; Lynne Campbell; Gaelle H Martin; Hadia Lemar; Thomas Cayton; Richard Y-C Huang; Xiaodi Deng; Akbar Nayeem; Haibin Chen; Burce Ergel; Joseph M Rizzo; Aaron P Yamniuk; Sanjib Dutta; Justine Ngo; Andrea Olga Shorts; Radha Ramakrishnan; Alexander Kozhich; Jim Holloway; Hua Fang; Ying-Kai Wang; Zheng Yang; Kader Thiam; Ginger Rakestraw; Arvind Rajpal; Paul Sheppard; Michael Quigley; Keith S Bahjat; Alan J Korman
Journal:  Nature       Date:  2019-10-23       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.